Companion Diagnostics Market is expected to generate a revenue of USD 12,150.01 Million by 2030, Globally, at 13.11% CAGR: Verified Market Research®
12 déc. 2022 09h30 HE
|
Verified Market Research
Jersey City, New Jersey, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Verified Market Research® recently published a report, “Companion Diagnostics Market” By Technology Type (Frequency Immunohistochemistry,...
Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting
05 déc. 2022 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration was well-tolerated, with notable seizure reduction reported in early data from the first two patients in Phase I/II clinical trial Additional preclinical data highlight...
Brain Scientific Inks Deal with Fulcrum to Go After At-Home Diagnostic Space, Hires VP of Marketing and Communications
01 déc. 2022 10h23 HE
|
Brain Scientific Inc.
LAKEWOOD RANCH, Fla., Dec. 01, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific (OTCQB:BRSF), a Florida-based applied science technology company, announces today a new distribution...
Zeto Implements encevis' Seizure Detection and Trending Algorithms
01 déc. 2022 08h00 HE
|
Zeto, Inc.
SANTA CLARA, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Zeto, Inc., an innovative EEG brain monitoring company, announced today the integration of FDA cleared seizure detection and trending...
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
29 nov. 2022 04h00 HE
|
AKAMPION
- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing...
Esoteric Testing Market Size & Share | North America, Europe, & APAC Industry Forecasts 2028: Graphical Research
22 nov. 2022 06h00 HE
|
Graphical Research
Pune, India, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The global esoteric testing market size is predicted to witness remarkable growth during the forecast period, owing to rise in the frequency of rare...
AB Science a reçu l’approbation de la Food and Drug Administration (FDA) américaine pour initier une étude confirmatoire de phase 3 avec le masitinib dans le traitement de la maladie d’Alzheimer
21 nov. 2022 12h09 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE A RECU L’APPROBATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE POUR INITIER UNE ÉTUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LE TRAITEMENT DE LA...
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
21 nov. 2022 12h09 HE
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE Paris,...
Praxis Precision Medicines to Present at Upcoming Investor Conferences
07 nov. 2022 09h00 HE
|
Praxis Precision Medicines, Inc.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Daniel Cloutier, a Veteran Sales Executive, Joins Brain Scientific as Chief Revenue Officer
01 nov. 2022 10h23 HE
|
Brain Scientific Inc.
LAKEWOOD RANCH, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific (OTCQB:BRSF), a Florida-based medical device technology company, announces today that Daniel Cloutier is...